Carbohydrate Conjugates as Delivery Agents for Oligonucleotides
    12.
    发明申请
    Carbohydrate Conjugates as Delivery Agents for Oligonucleotides 审中-公开
    碳水化合物缀合物作为寡核苷酸的递送剂

    公开(公告)号:US20150119445A1

    公开(公告)日:2015-04-30

    申请号:US14338161

    申请日:2014-07-22

    IPC分类号: A61K47/48 A61K31/713

    摘要: The present invention provides iRNA agents comprising at least one subunit of the formula (I): wherein: A and B are each independently for each occurrence O, N(RN) or S; X and Y are each independently for each occurrence H, OH, a hydroxyl protecting group, a phosphate group, a phosphodiester group, an activated phosphate group, an activated phosphite group, a phosphoramidite, a solid support, —P(Z′)(Z″)O-nucleoside, —P(Z′)(Z″)O-oligonucleotide, a lipid, a PEG, a steroid, a lipophile, a polymer, —P(Z′)(Z″)O-Linker-OP(Z′″)(Z″)O-oligonucleotide, a nucleotide, an oligonucleotide, —P(Z′)(Z″)-formula (I), —P(Z′)(Z″)- or -Linker-R; R is LG, -Linker-LG, or has the structure shown below: LG is independently for each occurrence a carbohydrate, e.g., monosaccharide, disaccharide, trisaccharide, tetrasaccharide, oligosaccharide, polysaccharide; RN is independently for each occurrence H, methyl, ethyl, propyl, isopropyl, butyl, or benzyl; and Z′, Z″, Z′″ and Z″″ are each independently for each occurrence O or S.

    摘要翻译: 本发明提供包含至少一个式(I)亚基的iRNA试剂:其中:A和B各自独立地为O,N(RN)或S; X和Y各自独立地为H,OH,羟基保护基,磷酸基,磷酸二酯基,活化磷酸酯基,活化亚磷酸酯基,亚磷酰胺,固体载体,-P(Z')( Z“)O-核苷,-P(Z')(Z”)O-寡核苷酸,脂质,PEG,类固醇,亲脂性,聚合物,-P(Z')(Z“)O-Linker- OP(Z')(Z“)O-寡核苷酸,核苷酸,寡核苷酸,-P(Z')(Z”) - 式(I),-P(Z')(Z“) - 或 - -R; R是LG,-Linker-LG,或具有如下结构:每次出现LG独立为碳水化合物,例如单糖,二糖,三糖,四糖,寡糖,多糖; 乙烯基,丙基,异丙基,丁基或苄基各自独立地为N, 和Z',Z“,Z”“和Z”“各自独立地为O或S.

    iRNA AGENTS WITH BIOCLEAVABLE TETHERS

    公开(公告)号:US20210254065A1

    公开(公告)日:2021-08-19

    申请号:US17243503

    申请日:2021-04-28

    IPC分类号: C12N15/113 C12N15/11

    摘要: The invention relates to iRNA agents, which preferably include a monomer in which the ribose moiety has been replaced by a moiety other than ribose that further includes a tether having one or more linking groups, in which at least one of the linking groups is a cleavable linking group. The tether in turn can be connected to a selected moiety, e.g., a ligand, e.g., a targeting or delivery moiety, or a moiety which alters a physical property. The cleavable linking group is one which is sufficiently stable outside the cell such that it allows targeting of a therapeutically beneficial amount of an iRNA agent (e.g., a single stranded or double stranded iRNA agent), coupled by way of the cleavable linking group to a targeting agent—to targets cells, but which upon entry into a target cell is cleaved to release the iRNA agent from the targeting agent.